



**Ingrezza® (valbenazine) Prior Authorization Form**

*Incomplete forms will not be reviewed*

*AIMS or TMC score sheet must be submitted*

**Maryland Medicaid  
Pharmacy Program**

Fax: (410) 333-5398

Phone: (833) 325-0105

Date: \_\_\_\_\_

**Patient Information**

Name: \_\_\_\_\_ DOB: \_\_\_\_\_

Medicaid Assistance Number: \_\_\_\_\_  M  F Height: \_\_\_\_\_ Weight: \_\_\_\_\_

**Prescriber Information**

Name: \_\_\_\_\_ NPI: \_\_\_\_\_

Contact Person for this Request:

Name: \_\_\_\_\_ Phone: \_\_\_\_\_ Fax: \_\_\_\_\_

**Diagnosis:**  Tardive dyskinesia (TD)  Chorea associated with Huntington’s disease (HD)  Other: \_\_\_\_\_

**Prescription Information**

Initial PA Request  Renewal PA Request

Strength:  Ingrezza initial pack  Ingrezza capsule(s) \_\_\_\_\_ mg

Instruction: \_\_\_\_\_

*Initial approval is for 90 days and renewal approval is for one year*

**Following criteria must be met and documents be submitted to review for both initial and renewal requests**

- Age ≥ 18 years
- Most recent progress notes
- Patient is NOT on other VMAT2 inhibitors or MAOI

*TD specific criteria:*

- Diagnosis of TD as defined by DSM-5
- AIMS score sheet, please submit  Initial score \_\_\_\_\_  Renewal score \_\_\_\_\_

*HD specific criteria*

- Total Maximal Chorea (TMC) score sheet, please submit  Initial score \_\_\_\_\_  Renewal score \_\_\_\_\_

**I attest that**

- Patient's lab/test results and clinical data will be evaluated and monitored.
- The requested medication is not part of a clinical trial and that the benefits of the treatment outweigh the risks and verify that the information provided on this form is true and accurate to the best of my knowledge.

MDH and prescriber acknowledge and agree that this request may be executed by electronic signature, which shall be considered as an original signature for all purposes and shall have the same force and effect as an original signature.

Prescriber’s Signature \_\_\_\_\_

Date \_\_\_\_\_